Methods of treating patients suffering from movement disorders

Abstract

The present invention is directed to methods of treating movement disorders by administering an effective amount of one or more adenosine A2A receptor antagonists to a patient in need thereof. The present invention also provides methods of decreasing the adverse effects of L-DOPA in patients receiving L-DOPA therapy in the treatment of Parkinson's disease. The present invention further provides methods and compositions for treating Parkinson's disease patients with sub-clinically effective doses of L-DOPA by combining L-DOPA treatment with an effective amount of one or more adenosine A2A receptor antagonists (i.e., L-DOPA sparing effect). The present invention further provides methods of effective treatment of Parkinson's disease by co-administering at least one adenosine A2A receptor antagonist, L-DOPA and a dopamine agonist and/or a COMT inhibitor and/or a MAO inhibitor. The present invention further provides methods of prolonging effective treatment of Parkinson's disease by administering an adenosine A2A receptor antagonist singly or together with a dopamine agonist, and/or a COMT inhibitor, and/or a MAO inhibitor without prior or subsequent administration of L-DOPA, delaying or removing on-set of L-DOPA motor complication.

1 - 50 . (canceled) 
     
     
         51 . A method of reducing or suppressing the adverse effectiveness of L-DOPA and/or dopamine agonist therapy, comprising administering an effective amount of (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methylxanthine or a pharmaceutically salt thereof to a Parkinson's disease patient. 
     
     
         52 . The method according to  claim 51 , wherein the patient suffers from L-DOPA- or other dopaminergic agent-induced motor complications. 
     
     
         53 . The method according to  claim 52 , wherein OFF time in motor fluctuations is reduced. 
     
     
         54 . The method according to  claim 52 , wherein dyskinesias in motor complications are improved. 
     
     
         55 . A method for L-DOPA sparing treatment comprising administering to a patient in need thereof a combination of a subclinically effective amount of L-DOPA and (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methylxanthine or a pharmaceutically acceptable salt thereof in an amount effective to render the L-DOPA efficacious. 
     
     
         56 . A composition for L-DOPA sparing treatment comprising a subclinically effective amount of L-DOPA and (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methylxanthine or a pharmaceutically acceptable salt thereof in an amount of effective to render the L-DOPA efficacious. 
     
     
         57 . A method of treating Parkinson's disease and L-DOPA motor complications, comprising administering an effective amount of (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methylxanthine or a pharmaceutically acceptable salt thereof in combination with at least one of a COMT, DA or MAO inhibitor to a patient in need thereof. 
     
     
         58 . A composition for the treatment of Parkinson's disease comprising an effective amount of (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methylxanthine or a pharmaceutically acceptable salt thereof, and a at least one of COMT, DA or MAO inhibitor. 
     
     
         59 . A method of prolonging effective treatment of Parkinson's disease comprising administering either (i) (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methylxanthine or a pharmaceutically acceptable salt thereof, or (ii) (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methylxanthine or a pharmaceutically acceptable salt thereof and a dopamine agonist to a patient in need thereof in an amount effective to delay or remove the patient's need for add-on L-DOPA therapy. 
     
     
         60 . A method of treating movement disorders comprising administering an effective amount of (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methylxanthine or a pharmaceutically acceptable salt thereof to a patient in need thereof. 
     
     
         61 . The method according to  claim 60 , wherein the patient suffers from tremors, bradykinesias, shuffling gait, dystonias, dyskinesias, tardive dyskinesias or other extrapyramidal syndromes.